Khaled Musallam/LinkedIn
Aug 13, 2026, 11:05
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:
“Pleased to share our latest ‘2026 Update on Clinical Trials in β-Thalassemia,’ published today in the American Journal of Hematology.
It is incredibly fulfilling to reflect on how much the field has advanced since our last update in 2021 with new approvals and an expanding pipeline continuing to reshape the treatment landscape for β-thalassemia.”
Title: 2026 Update on Clinical Trials in β-Thalassemia
Authors: Khaled M. Musallam, Franco Locatelli, Mattia Algeri, Maria Domenica Cappellini, Ali T. Taher
Stay updated with Hemostasis Today.
-
Sep 2, 2026, 15:41Nour Al-Mozain: Rethinking the Role of Cold-Stored Platelets
-
Sep 2, 2026, 15:39Fahad Alshehri: Are All Platelets Created Equal?
-
Sep 2, 2026, 15:09Kim Cook: Bringing Rare Blood Cancers Into the Conversation
-
Sep 2, 2026, 15:08Anupriya Ak: Blood Groups and Transfusion Compatibility
-
Sep 2, 2026, 14:51Amir Hesam Karbakhsh: The Science Behind Platelet-Rich Plasma Preparation
-
Sep 2, 2026, 14:38Brandi Littles Kelly: Raising ITP Awareness Through a Family’s Journey
-
Sep 2, 2026, 14:36Sangita Saha: Hemolysis in Hemodialysis – Causes, Prevention, Patient Safety
-
Sep 2, 2026, 14:31David Smadja: A New School Year, A Stronger Hematology Team
-
Sep 2, 2026, 14:28Khaled Musallam: The 5th MENA Congress for Rare Diseases Is Coming to Abu Dhabi